Pregabalin Capsule
Product Images NDC 71335-1459

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351459)

Label for Pregabalin Capsules, USP 150 mg by Bryant Ranch Prepack, containing 30 capsules. The label includes the NDC 71335-1459-01, a barcode, and storage instructions. It states the product is Rx only and repackaged by Bryant Ranch Prepack, Inc., Burbank, CA.*

FDA Label Image

Label (Lbl7133514592)

Label for Pregabalin 150 mg (CV) capsule, packaged by Bryant Ranch Prepack. The label states it is a white capsule, to compare to Lyrica 150 mg (CV) capsule by Laurus Labs Limited. The package contains 30 capsules. Storage instructions indicate room temperature of 20-25°C (68-77°F). It includes a barcode and the NDC number 71335-1459-1.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of pregabalin, showing its molecular framework with an amino group and a carboxylic acid group attached to a branched carbon chain.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

An image showing a formula for calculating creatinine clearance (CLCr). The formula uses variables including age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. This formula is often used to estimate kidney function.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 200 mg, 100 mg, 25 mg three times a day, and placebo. The y-axis represents percent of patients improved, while the x-axis shows percent improvement in pain from baseline.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A cumulative distribution plot showing percent of patients improved versus percent improvement in pain from baseline. Two treatment groups are compared: Pregabalin 100 mg three times a day (dashed line) and placebo (dotted line). The graph illustrates patient response rates at various thresholds of percent pain improvement.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line chart showing percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 300 mg, 150 mg, 75 mg taken two times a day, and placebo. Each dosage level is represented by a different line style, illustrating the varying degrees of pain improvement among groups.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph comparing percent improvement in pain from baseline against percent of patients improved for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three descending curves, indicating patient response rates across various pain improvement thresholds.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph illustrates patient improvement trends for the two Pregabalin doses against placebo.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

A bar graph comparing responder rates (%) between placebo and various dosages of Pregabalin in two studies, E1 and E3. The X-axis represents different treatment groups including placebo and Pregabalin doses (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day). The Y-axis shows responder rates from 0 to 60%. Both studies show higher responder rates for Pregabalin doses compared to placebo, with statistical significance indicated. Study E1 has five groups; Study E3 has three groups.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percentage change from baseline on the vertical axis versus dose in mg/day on the horizontal axis for PREGABALIN 150 mg. The graph compares four studies (E1 BD, E2 TID, E3 BD, and E3 TID) showing seizure reduction at doses of 50, 150, 300, and 600 mg/day, with significant p-values indicated for each data point.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares four groups: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, with patient improvement percentages on the y-axis and pain improvement percentages on the x-axis.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A Kaplan-Meier survival curve showing the estimated percentage of subjects without LTR (loss to response) over 180 days. The chart compares two groups: Pregabalin (solid line) and Placebo (dashed line). The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis represents days from 0 to 180.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 between Pregabalin and Placebo groups. The x-axis represents percent improvement, while the y-axis shows the percent of subjects improved. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, indicating higher improvement rates with Pregabalin.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line graph comparing the percentage of subjects improved on the vertical axis against the percent improvement from baseline to week 16 on the horizontal axis. Two lines represent Pregabalin and Placebo groups, showing a higher percentage of subjects improved with Pregabalin across increasing improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.